Incidence of Outcomes Per 1,000 Women
| Tamoxifen | Raloxifene | RR, 95% CI | |
| CI = confidence interval; RR = relative risk; VTE = venous thromboembolism. | |||
| Invasive breast cancer | 4.3 | 4.41 | 1.02, 0.82–1.28 |
| Noninvasive breast cancer | 1.51 | 2.11 | 1.4, 0.98–2.00 |
| Uterine cancer | 2.0 | 1.25 | 0.62, 0.35–1.08 |
| VTE | 3.8 | 2.6 | 0.7, 0.68–0.99 |
| Cataracts | 12.3 | 9.72 | 0.79, 0.68–0.92 |
| Incidence of Symptoms (0–4 scale) | |||
| Favor Tamoxifen | |||
| Dyspareunia | 0.68 | 0.78 | P < .001 |
| Musculoskeletal problems | 1.10 | 1.15 | P = .002 |
| Weight gain | 0.76 | 0.82 | P < .001 |
| Favor Raloxifene | |||
| Vasomotor symptoms | 0.96 | 0.85 | P < .001 |
| Bladder control symptoms | 0.88 | 0.73 | P < .001 |
| Leg cramps | 1.10 | 0.91 | P < .001 |
| Gynecologic problems | 0.29 | 0.19 | P < .001 |
